Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration

详细信息    查看全文

• 作者：Marko ?krti? (1)
  Gary K. Yang (1)
  Bruce A. Perkins (2)
  Nima Soleymanlou (3)
  Yuliya Lytvyn (1)
  Maximilian von Eynatten (4)
  Hans J. Woerle (5)
  Odd Erik Johansen (6)
  Uli C. Broedl (5)
  Thomas Hach (5)
  Melvin Silverman (1)
  David Z. I. Cherney (1)
  
• 关键词：Diabetes ; Renal hyperfiltration ; SGLT2 inhibition
• 刊名：Diabetologia
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：57
• 期：12
• 页码：2599-2602
• 全文大小：180 KB
• 参考文献：1. Hostetter TH, Rennke HG, Brenner BM (1982) The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 72:375-80 CrossRef
  2. Gomez DM (1951) Evaluation of renal resistances, with special reference to changes in essential hypertension. J Clin Invest 30:1143-155 CrossRef
  3. Cherney DZI, Perkins BA, Soleymanlou N et al (2014) Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129:587-97 CrossRef
  4. Cherney DZ, Perkins BA, Soleymanlou N et al (2014) The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol 13:28 CrossRef
  5. Perkins BA, Cherney DZ, Partridge H et al (2014) Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care 37:1480-483 CrossRef
  6. Vallon V, Richter K, Blantz RC, Thomson S, Osswald H (1999) Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. J Am Soc Nephrol 10:2569-576
  7. Luik PT, Hoogenberg K, van Der Kleij FG et al (2002) Short-term moderate sodium restriction induces relative hyperfiltration in normotensive normoalbuminuric type I diabetes mellitus. Diabetologia 45:535-41 CrossRef
  8. Investigators O, Yusuf S, Teo KK et al (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358:1547-559 CrossRef
  9. Parving H-H, Brenner BM, McMurray JJV et al (2012) Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367:2204-213 CrossRef
  10. Fried LF, Emanuele N, Zhang JH et al (2013) Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 369:1892-903 CrossRef
  
• 作者单位：Marko ?krti? (1)
  Gary K. Yang (1)
  Bruce A. Perkins (2)
  Nima Soleymanlou (3)
  Yuliya Lytvyn (1)
  Maximilian von Eynatten (4)
  Hans J. Woerle (5)
  Odd Erik Johansen (6)
  Uli C. Broedl (5)
  Thomas Hach (5)
  Melvin Silverman (1)
  David Z. I. Cherney (1)
  
  1. Department of Medicine, Division of Nephrology, Toronto General Hospital, University of Toronto, 585 University Ave, 8N-845, Toronto, ON, Canada, M5G 2N2
  2. Department of Medicine, Division of Endocrinology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada
  3. Boehringer Ingelheim Canada, Burlington, ON, Canada
  4. Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA
  5. Boehringer Ingelheim Pharma GmbH & Co.KG, Ingelheim, Germany
  6. Boehringer Ingelheim Norway KS, Asker, Norway
  
• ISSN：1432-0428

文摘